Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Activity of Adenylyl Cyclase Type 6 Is Suppressed by Direct Binding of the Cytoskeletal Protein 4.1G

Masaki Saito, Linran Cui, Marina Hirano, Guanjie Li, Teruyuki Yanagisawa, Takeya Sato and Jun Sukegawa
Molecular Pharmacology October 2019, 96 (4) 441-451; DOI: https://doi.org/10.1124/mol.119.116426
Masaki Saito
Department of Molecular Pharmacology, Tohoku University School of Medicine, Sendai, Miyagi, Japan (M.S., L.C., M.H., G.L., T.Y., T.S., J.S.); Department of Human Health and Nutrition, Shokei Gakuin University, Natori, Miyagi, Japan (M.H., J.S.); and Faculty of Health Sciences, Tohoku Fukushi University, Sendai, Miyagi, Japan (T.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linran Cui
Department of Molecular Pharmacology, Tohoku University School of Medicine, Sendai, Miyagi, Japan (M.S., L.C., M.H., G.L., T.Y., T.S., J.S.); Department of Human Health and Nutrition, Shokei Gakuin University, Natori, Miyagi, Japan (M.H., J.S.); and Faculty of Health Sciences, Tohoku Fukushi University, Sendai, Miyagi, Japan (T.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marina Hirano
Department of Molecular Pharmacology, Tohoku University School of Medicine, Sendai, Miyagi, Japan (M.S., L.C., M.H., G.L., T.Y., T.S., J.S.); Department of Human Health and Nutrition, Shokei Gakuin University, Natori, Miyagi, Japan (M.H., J.S.); and Faculty of Health Sciences, Tohoku Fukushi University, Sendai, Miyagi, Japan (T.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guanjie Li
Department of Molecular Pharmacology, Tohoku University School of Medicine, Sendai, Miyagi, Japan (M.S., L.C., M.H., G.L., T.Y., T.S., J.S.); Department of Human Health and Nutrition, Shokei Gakuin University, Natori, Miyagi, Japan (M.H., J.S.); and Faculty of Health Sciences, Tohoku Fukushi University, Sendai, Miyagi, Japan (T.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teruyuki Yanagisawa
Department of Molecular Pharmacology, Tohoku University School of Medicine, Sendai, Miyagi, Japan (M.S., L.C., M.H., G.L., T.Y., T.S., J.S.); Department of Human Health and Nutrition, Shokei Gakuin University, Natori, Miyagi, Japan (M.H., J.S.); and Faculty of Health Sciences, Tohoku Fukushi University, Sendai, Miyagi, Japan (T.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takeya Sato
Department of Molecular Pharmacology, Tohoku University School of Medicine, Sendai, Miyagi, Japan (M.S., L.C., M.H., G.L., T.Y., T.S., J.S.); Department of Human Health and Nutrition, Shokei Gakuin University, Natori, Miyagi, Japan (M.H., J.S.); and Faculty of Health Sciences, Tohoku Fukushi University, Sendai, Miyagi, Japan (T.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Sukegawa
Department of Molecular Pharmacology, Tohoku University School of Medicine, Sendai, Miyagi, Japan (M.S., L.C., M.H., G.L., T.Y., T.S., J.S.); Department of Human Health and Nutrition, Shokei Gakuin University, Natori, Miyagi, Japan (M.H., J.S.); and Faculty of Health Sciences, Tohoku Fukushi University, Sendai, Miyagi, Japan (T.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    AC6 interacts with 4.1G in vivo. (A) Intracellular distribution of GFP-AC6-FL and FLAG-4.1G-FL. HEK293 cells stably expressing GFP-AC6-FL were transiently expressed with FLAG-4.1G-FL. The cells were colabeled with rabbit anti-GFP antibody (green) and mouse anti-FLAG antibody (clone M2, red). The boxed area indicates the enlarged region. One of the representative 10 images is shown. Scale bar, 10 μm. (B) Fluorescence intensity (F.I.) profile plots from (a) to (a’) shown in (A). Arrowheads indicate the position of the cell periphery. (C) Interaction of GFP-AC6-FL and endogenous 4.1G in HEK293 cells. Parental HEK293 cells or HEK293 cells stably expressing GFP-AC6-FL (GFP-AC6-FL/HEK293) were subjected to a coimmunoprecipitation assay. Mouse anti-GFP antibody (mFX73) or mouse anti-DYKDDDDK antibody as a negative control was used for immunoprecipitation. Both immunoprecipitants (IP) and whole lysates were immunoblotted (IB) with rabbit anti-4.1G or rabbit anti-GFP antibody. Representative immunoblots of five independent experiments are shown.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    The N-terminus of AC6 directly binds to the FERM domain of 4.1G. (A) Schematic of the domain structure of AC6. AC6 consists of five domains: the N-terminus (N), the first six-transmembrane domain (TM1), the first cytoplasmic loop (C1), the second six-transmembrane domain (TM2), and the second cytoplasmic loop (C2). Intracellular subdomains of AC6 were fused with maltose binding protein (MBP) to produce MBP-AC6-N, MBP-AC6-C1, and MBP-AC6-C2, respectively. (B) Schematic of the domain structure of 4.1G. 4.1G is composed of four major domains: the headpiece (HP), the 4.1-ezrin-moesin-radixin domain (FERM), the spectrin-actin binding domain (SABD), and the carboxy-terminal domain (CTD). Subdomains of 4.1G were FLAG-tagged to produce FLAG-4.1G-HP, FLAG-4.1G-FERM, and FLAG-4.1G-SABD/CTD, respectively. (C) In vitro pull-down assay. MBP or MBP-AC6 proteins were incubated with FLAG-4.1G proteins and further incubated with amylose resin beads. Proteins bound to the amylose resin were separated by SDS-PAGE and detected by immunoblotting (IB) by using mouse anti-DYKDDDDK antibody (upper). MBP or MBP-AC6 proteins purified by amylose resin beads were stained with CBB (lower). (-): MBP (43 kDa); N: MBP-AC6-N (59 kDa); C1: MBP-AC6-C1 (82 kDa); and C2: MBP-AC6-C2 (68 kDa). Arrowheads indicate the apparent molecular weight of FLAG-4.1G-HP (26 kDa), -FERM (36 kDa), and -SABD/CTD (58 kDa). Representative immunoblots of three independent experiments are shown.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    AC6-N is associated with the plasma membrane via 4.1G. (A) Intracellular distribution of GFP-AC6-N and FLAG-4.1G-FL. HEK293 cells transiently expressed with GFP-AC6-N and FLAG-4.1G-FL were labeled with rabbit anti-GFP (green) and mouse anti-FLAG (clone M2, red) antibodies. The boxed areas indicate the enlarged regions. One of the representative 16 images is shown. Scale bar, 10 μm. (B) Fluorescence intensity (F.I.) profile plots from (a) to (a’) shown in (A). Arrowheads indicate the position of the cell periphery. (C) Plasma membrane distribution of GPF-AC6-N. HEK293 cells expressing both GPF-AC6-N and DsRed-TMD were also transfected with (lower) or without (upper) 4.1G-siRNA (4.1G-si). The cells fixed with 4% PFA were observed by confocal microscopy without immunolabeling. One representative image from each transfection is shown. The boxed areas indicate the enlarged regions. Scale bar, 10 μm. (D) Quantification of the fluorescence intensity of GFP-AC6-N distributed at DsRed-TMD-labeled plasma membrane (PM) region in (C). n = 16 (control) or 23 (4.1G-si). Data are presented as the means ± S.D. Student’s t test was performed for statistical analysis. (E) Knockdown efficiency of 4.1G-si in HEK293 cells. The cell lysates were immunoblotted (IB) with rabbit anti-4.1G or mouse anti-GAPDH antibody. Representative immunoblots of three independent experiments are shown.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    4.1G does not affect the plasma membrane distribution of GPF-AC6-FL. (A) Intracellular distribution of GFP-AC6-FL. HEK293 cells transiently expressed with both GFP-AC6-FL and DsRed-TMD were further transfected with (lower) or without (upper) of 4.1G-siRNA (4.1G-si). The cells fixed with 4% PFA were observed by confocal microscopy without immunolabeling. One representative image from each transfection is shown. The boxed areas indicate the enlarged regions. Scale bar, 10 μm. (B) Quantification of the fluorescence intensity of GFP-AC6-FL distributed at DsRed-TMD-labeled plasma membrane (PM) region in (A). n = 22 (control) or 30 (4.1G-si). Data are presented as the means ± S.D. Student’s t test was performed for statistical analysis.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    The three consecutive arginine sequence in the N-terminus of AC6 is essential for binding to the FERM domain of 4.1G. (A) Amino acid sequences of AC6-Ns. Triple-arginine and triple-alanine sequences in AC6-N and AC6-N-3A are underlined. Amino acid residues are numbered above the sequences. (B) In vitro pull-down assay of MBP-AC6-Ns and FLAG-4.1G-FERM. FLAG-4.1G-FERM that bound to MBP-AC6-Ns (212 nM) were visualized by SDS-PAGE and immunoblotting (IB) using mouse anti-DYKDDDDK antibody (upper). FLAG-4.1G-FERM proteins contained in the lysates were immunoblotted with anti-DYKDDDDK antibody (middle). MBP and MBP-AC6-Ns pulled down by amylose resin beads were separated by SDS-PAGE and visualized by CBB staining (lower). MBP (-) (43 kDa), MBP-AC6-N (59 kDa), MBP-AC6-N-3A (59 kDa), and FLAG-4.1G-FERM (36 kDa). Representative immunoblots of three independent experiments are shown. (C) Plasma membrane distribution of GPF-AC6-N or -3A. HEK293 cells were expressed with GPF-AC6-N or -3A in the presence of DsRed-TMD. The cells fixed with 4% PFA were observed by confocal microscopy without immunolabeling. One representative image from each transfection is shown. The boxed areas indicate the enlarged regions. Scale bar, 10 μm. (D) Quantification of the fluorescence intensities of GFP-AC6-N or -3A distributed at DsRed-TMD-labeled plasma membrane (PM) region in (C). n = 26 (WT) or 26 (3A). Data are presented as the means ± S.D. Student’s t test was performed for statistical analysis.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    The association of AC6-N with the plasma membrane is critical for AC6 activity. (A and B) Effect of (A) overexpression of GFP-AC6-Ns or (B) knockdown of 4.1G in forskolin-induced cAMP production. HEK293 cells were exogenously expressed with (A) GFP-AC6-N or -3A or (B) transfected with 4.1G-shRNA (4.1G-sh). The cells were treated with 10 μM forskolin (FK) in the presence of 100 μM IBMX for 10 minutes at 37°C. (C and D) Effect of (C) overexpression of GFP-AC6-Ns or (D) knockdown of 4.1G in PTH-(1-34)-induced cAMP production. HEK293 cells stably expressing HA-PTHR were transiently expressed with (C) GFP-AC6-N or -3A or (D) transfected with 4.1G-sh. The cells were treated with 10 nM PTH-(1-34) in the presence of 100 μM IBMX for 14 minutes at 37°C. The intracellular cAMP concentration was analyzed by AlphaScreen cAMP assay as described in Materials and Methods. (A and C) Data are presented as the means ± S.E.M., n = 3; one-way analysis of variance followed by Tukey’s tests were performed within the drug-treated cells. (B and D) Data are presented as the means ± S.E.M., n = 3, Student’s t tests were performed between the drug-treated cells.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    The expression of endogenous AC6 protein is not altered by AC6-N-expression or 4.1G-knockdown. (A) Expression of endogenous AC6 protein in HEK293 cells transiently expressing GFP, GFP-AC6-N, or GFP-AC6-N-3A was detected by Western blotting. The samples were immunoblotted (IB) with rabbit anti-AC6 antibody, rabbit anti-GFP antibody, or mouse anti-GAPDH antibody. (B) Quantification of (A). Data are presented as the means ± S.D. from three independent experiments. (C) Expression of endogenous AC6 protein in HEK293 cells transfected with 4.1G siRNA cocktail. The samples were immunoblotted (IB) with rabbit anti-AC6 antibody, rabbit anti-4.1G antibody, or mouse anti-GAPDH antibody. (D) Quantification of (C). Data are presented as the means ± S.D. from two independent experiments.

  • Fig. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    Theoretical models. (A) In normal condition, the three consecutive arginine sequence (RRR) in the N-terminus of AC6 is associated with the plasma membrane via 4.1G, and AC6 activity is restricted. (B) When the N-terminus of AC6 is dissociated from the plasma membrane (e.g., lower expression level of 4.1G or overexpression of AC6-N), AC6 activity is high.

Additional Files

  • Figures
  • Data Supplement

    • Supplemental Figures -

      Supplementary Figure 1 -  Identification of FLAG-4.1G proteins in E. coli, and exogenously expressed GFP-AC6 proteins and FLAG-4.1G-FL protein in HEK293 cells.

      Supplementary Figure 2 -  Amino acid sequences of the intracellular subdomains of human AC6.

      Supplementary Figure 3 - The binding affinity of MBP-AC6-N and FLAG-4.1G-FERM proteins.

      Supplementary Figure 4 -  Intracellular localization of GFP-AC6-Ns and FLAG-4.1G-FL.

      Supplementary Figure 5 - The three consecutive positive charges in the N-terminus of AC6 are essential for binding to the FERM domain of 4.1G.

      Supplementary Figure 6 - Binding of the N-termini of MBP-ACs with FLAG-4.1G-FERM.

      Supplementary Figure 7 - A dose-dependent increase in cAMP production by PTH-(1-34).

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 96 (4)
Molecular Pharmacology
Vol. 96, Issue 4
1 Oct 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Activity of Adenylyl Cyclase Type 6 Is Suppressed by Direct Binding of the Cytoskeletal Protein 4.1G
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Activity of AC6 Is Suppressed by Direct Binding of 4.1G

Masaki Saito, Linran Cui, Marina Hirano, Guanjie Li, Teruyuki Yanagisawa, Takeya Sato and Jun Sukegawa
Molecular Pharmacology October 1, 2019, 96 (4) 441-451; DOI: https://doi.org/10.1124/mol.119.116426

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Activity of AC6 Is Suppressed by Direct Binding of 4.1G

Masaki Saito, Linran Cui, Marina Hirano, Guanjie Li, Teruyuki Yanagisawa, Takeya Sato and Jun Sukegawa
Molecular Pharmacology October 1, 2019, 96 (4) 441-451; DOI: https://doi.org/10.1124/mol.119.116426
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • GABAAR Molecular Identity in Oligodendrocytes
  • Editing TOP2α Intron-19 5′ SS Circumvents Drug Resistance
  • SerpinA3N and drug induced liver injury
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics